Heart failure & cardiomyopathies
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC
An erratum to this article was published (Europace, 7 May 2025 ↗)
Recommendations
As issued by the authors
Rule out reversible causes of arrhythmias, which in LVAD patients may include mechanical irritation from the inflow cannula and suction events
For symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant
The peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future ventricular tachycardia (VT) recurrences
Original publication
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device’s patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC. Europace. Published 31 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →